A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors.
| Image |  |
|---|---|
| Description | scientific article |
| Author/s |
author: Adam Patterson Bill Denny |
| Publication date | December 10, 2009 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |